Company intelligence / Profile preview

Tyrogenex

West Palm Beach, Florida, United Statesx.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Tyrogenex developed X‑82, an orally administered dual VEGFR/PDGFR inhibitor. Early clinical results showed that X‑82 was well tolerated in Phase I studies for advanced solid tumors and demonstrated preliminary anti-tumor activity. A Phase II study in wet AMD was planned. The company focused on developing targeted therapies with reduced toxicity compared to existing options[3].

Therapeutic areas: OphthalmologyOncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

vorolanib

Phase 2

Indications: Wet age-related macular degeneration, Renal cell carcinoma, Solid tumors, Pancreatic neuroendocrine tumors

Partnerships

Brace Pharma

Beyond the preview

Go deeper on Tyrogenex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tyrogenex.

Explore the full profile